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Abstract
Environmental exposures during pregnancy may increase breast cancer risk for mothers and 
female offspring. Tumor tissue assays may provide insight regarding the mechanisms. This study 
assessed the feasibility of obtaining tumor samples and pathology reports from mothers (F0) who 
were enrolled in the Child Health and Development Studies during pregnancy from 1959 to 1967 
and their daughters (F1) who developed breast cancer over more than 50 years of follow-up. 
Breast cancer cases were identified through linkage to the California Cancer Registry and self-
report. Written consent was obtained from 116 F0 and 95 F1 breast cancer survivors to access their 
pathology reports and tumor blocks. Of those contacted, 62% consented, 13% refused and 24% 
did not respond. We obtained tissue samples for 57% and pathology reports for 75%, and if 
diagnosis was made ⩽ 10 years we obtained tissue samples and pathology reports for 91% and 
79%, respectively. Obtaining pathology reports and tumor tissues of two generations is feasible 
and will support investigation of the relationship between early-life exposures and molecular 
tumor markers. However, we found that more recent diagnosis increased the accessibility of tumor 
tissue. We recommend that cohorts request consent for obtaining future tumor tissues at study 
enrollment and implement real-time tissue collection to enhance success of collecting tumor 
samples and data.
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Introduction
Pregnancy and intrauterine life are two critical periods when human breasts are most 
susceptible to environmental exposure.1,2 The Child Health and Development Studies 
(CHDS) has shown a strong association between breast cancer and 
p,p’dichlorodiphenyltrichloroethane (DDT) levels measured during pregnancy, particularly 
among women who were under the age of 14 in 1945 when DDT was introduced,3 and that 
DDT exposure in utero is associated with a nearly four-fold increased risk of breast cancer 
in daughters.4
The CHDS is comprised of parents and their offspring enrolled during the women’s 
pregnancies from 1959 to 1966. CHDS parents and offspring have been followed-up for 
cancer incidence over more than 57 years, presenting a unique opportunity for prospective 
studies of cancer beginning during pregnancy in mothers and during fetal life in offspring. 
Collection of tumor tissue and related pathology reports for information on tumor markers 
may help us understand the etiology of cancer. For this reason, we initiated a pilot study to 
determine the feasibility of collecting tumor tissue from breast cancer cases identified in the 
CHDS. This was the first attempt to collect pathology reports and tumor specimens from the 
CHDS, and we report on our experience in this article.
Methods
This study was made possible by a prospective follow-up of the CHDS, a pregnancy cohort 
of over 15,000 families who were enrolled between 1959 and 1966 during the mothers’ 
pregnancies (with deliveries extending into 1967). All mothers in the Child Health and 
Development Studies cohort were recruited from the Kaiser Foundation Health Plan in the 
East Bay of the San Francisco Bay Area. Cohort enrollment and baseline biospecimen and 
data collection methods have been described previously.5 In this study, we tested the 
feasibility of collecting tumor tissue samples and pathology reports from two generations of 
women, the founding mothers (F0) and their daughters (F1).
Eligible F0 cases were diagnosed by the age of 54 years. No age cut-off was imposed for the 
F1 generation, and the age range of F1 at diagnosis was 47–54 years. The years of diagnosis 
ranged from 1962 to 2012 in the F0 generation and from 1997 to 2013 in the F1 generation. 
Cases were identified by linkage to the California Cancer Registry (CCR) and the California 
Vital Status Records as well as by self-report during a survey of CHDS daughters conducted 
from 2010 to 2013. Essentially all eligible surviving F0 cases were identified through the 
CCR linkage. F1 living cases were identified by self-report to the CHDS only (n = 28) or by 
linkage to CCR only (n = 23), or both (n = 44). F0 diagnoses spanned over 50 years, the 
earliest diagnosis was 51 years before this study and the latest was 1 year before this study. 
In contrast, F1 diagnoses occurred within a much more compressed time span; the earliest 
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diagnosis was 16 years before this study and the latest diagnoses were ascertained 
concurrent with this study. We invited surviving cases with a valid address (F0, n = 116; F1, 
n = 95) to provide access to their pathology reports and tumor samples. To determine the 
feasibility of acquiring tumor samples from deceased cases, we also attempted to collect 
tumor tissue and pathology reports for a small convenience sample of deceased cases in F0 
(n = 26) and F1 (n = 10).
The present study was reviewed and approved by the Institutional Review Board (IRB) of 
the Public Health Institute and the California Committee for the Protection of Human 
Subjects. Informed consent was obtained from all participants, and we have complied with 
all federal guidelines governing the use of human participants.
Consent and tissue acquisition
To recruit living breast cancer cases to this study, we mailed participants an invitation packet 
consisting of an invitation letter describing the study, a ‘Consent to Authorize Use of 
Medical Information’ form, a ‘Consent to Authorize Release of Medical Information’ form 
and a ‘Consent to Participate in a Research Study’ form. To obtain death certificates for 
deceased cases, we submitted requests to the California Department of Health Vital Records 
Office.
Once consent from living participants or death certificates were received, tumor block and 
pathology report request forms were faxed to the pathology department of the hospital 
designated on the medical release form or the physician of record on the death certificate. 
Tissue sample and pathology request forms were accompanied by the study IRB approval 
letter, participant consent and authorization forms or death certificates. Faxes were followed-
up by phone calls to pathology departments to determine sample availability.
Upon arrival, all identifying personal information was removed from tumor samples and 
pathology reports and replaced with a sample identification number. Pathology reports were 
received either in paper or in electronic form via fax, email and mail. Cancer classification 
variables (hormone receptor status, histopathology, grade and stage of breast cancer) were 
extracted from the reports. Estrogen receptor, progesterone receptor and human epidermal 
growth factor receptor 2 statuses were recorded when available.
Tumor block criteria
Samples were received in the form of formalin-fixed, paraffin-embedded tissues (tumor 
blocks) or slides. If slides were sent from the hospital, seven sections of tissue were 
requested for DNA extraction (7-μm thick, one section for hematoxylin and eosin staining), 
measuring 2 × 2-cm, assuming the tissue was >90% cancer. If the percentage of cancer 
tissue was <90%, two more sections were requested.
Results
Access to CHDS breast cancer cases via the CCR
The CCR provided contact information for less than half of the living F1 cases who were 
found on the CCR (n = 46 of 98 submitted) because they were already participants in a 
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current CCR study. This is the main enrollment barrier for CCR-identified F1 participants in 
the CHDS. We did not encounter the same limitation for the F0 cancer cases as they were 
diagnosed many years ago and were less likely to be active participants in other CCR 
studies. As many of the F1 cases withheld by CCR self-reported their cancer directly to us in 
a recent survey and consented for future contact, we were able to include some of the 
women withheld by CCR in our study (n = 22). This result emphasizes the importance of 
active cohort follow-up for obtaining medical records and tumor tissue samples.
Deceased cases
We requested death certificates for 26 F0 cases and received 24 certificates (92%). A total of 
13 certificates provided valid physician information. Among these, we acquired tumor 
specimens with pathology reports for four cases and only the pathology report for one case. 
We requested death certificates for ten F1 cases and received all certificates (100%). Nine 
provided valid physician information. Among those, we received tumor specimens with 
pathology reports for three cases.
Consent and tissue acquisition for surviving cases
The response rates are presented in Table 1 for both F0 and F1 living cases. The participants 
who consented had an age range of 57 to 93 years, with breast cancer diagnoses occurring as 
far back as 45 years. Race and location of participants are presented in Table 2. Among F0 
with breast cancer, a total of 116 were eligible, and 69 were contacted; 46 of 69 participants 
(67%) provided consent (Table 1, F0). Of those, we received tissue samples for 14 cases (13 
with pathology reports) and only pathology reports for 12 cases. Among F1 cases who were 
living, 95 were eligible, and 87 were successfully contacted; 52 of 87 participants (60%) 
provided consent (Table 1, F1). Of those, we received tissue samples with pathology reports 
for 42 and pathology reports only for six cases.
For tumor tissue collection, we contacted a total of 49 hospitals. Among them 38 hospitals 
were in California and 11 were out of state (over 90% of the samples were requested from 
California hospitals). It took an average of 4.5 (±2.3) provider/hospital contacts by phone 
and fax to receive tumor samples, pathology reports or notification that no samples were 
available. The cost of samples ranged from US$0 to $293 with an average per sample cost of 
$47, which was slightly under the budgeted sample cost of $50 (Supplementary Table S1).
Although we were able to collect tissue from cases diagnosed as far back as 1982, we found 
that tissue samples from cases diagnosed over 2 decades ago were difficult to obtain because 
the majority of hospitals only keep tumor samples and pathology reports for 10–15 years 
(Fig. 1). The majority of F1 breast cancer diagnoses fall within the last 10 years. As a result, 
81% of F1 tumor samples were collected from cases who consented and only 30% for F0. 
Overall, for both F1 and F0 generations combined, we collected pathology reports for 75% 
of living cases requested and tissue samples for 57% of living cases requested.
We gathered data from other prospective cancer cohort studies (Nurses’ Health Study, 
Health Professionals Follow-up Study, Women’s Health Initiative Cohort Study, Breast 
Cancer Family Registry Cohort and Sister Study) to compare tumor tissue collection consent 
rates.6–9 Even though these studies had different designs and not all had published tissue 
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consent rates, the approximate tissue consent rates were reported by principal investigators 
and study managers. In studies that received consent at diagnosis or after, tumor tissue 
consent rates ranged from 50 to 96%.6–9 Studies that asked for consent before diagnosis 
reported a >90% consent rate. This suggests that obtaining broad consent before diagnosis 
results in greater access to tumor tissue than studies that sought tumor tissue consent at or 
after the time of diagnosis.
Discussion
This pilot study establishes the feasibility of obtaining IRB approval, obtaining participant 
consent and collecting tumor tissue samples for cancer cases in our long-term cohort that 
had cancer diagnoses at multiple facilities and belong to a variety health plans. This is 
consistent with another California study that successfully collected tumor samples going 
back 60 years among women who were members of the Kaiser Permanente Northern 
California health plan.10 In our study, we identified two substantial barriers to tumor 
collection. First, the CCR policy of only releasing contact of cancer survivors not already in 
another CCR study limited access to CHDS cohort cancer cases. Second, collecting samples 
when the diagnosis was made over a decade ago restricted access to tissue samples. Both 
these barriers can be addressed by active and ongoing follow-up of cohort members to 
obtain prompt self-report of cancer diagnosis.
We submitted all known breast cancer cases to the CCR in order to obtain contact 
information. CCR’s policy is to only release cases for contact who are not already part of an 
active CCR cancer study. They do this to prevent multiple researchers from contacting 
cancer patients within a short period to mitigate patient burden.11 Thus, CCR provided 
contact information about less than half of the living F1 cases submitted. Active follow-up 
provides the opportunity for collecting tumor samples from survivors that would have 
otherwise been inaccessible through CCR. It also empowers patients and survivors by giving 
them the ability to make an active choice to participate. The idea that cancer survivors want 
to participate in multiple studies is supported by the high participation rate of women who 
self-reported and were withheld by CCR. By obtaining trust and consent well in advance of 
diagnosis, we believe we can alleviate potential stress and inconvenience to cancer patients 
and survivors after diagnosis from being asked to participate in a cancer study.
Collection of samples and pathology reports for cancer diagnosed ⩽ 10 years ago has the 
highest feasibility as older samples and reports are more likely to have been discarded or 
lost. On the basis of our success in collecting pathology reports (92%) and tissue samples 
(81%) from F1 that have more recent diagnoses, collection of tumor samples from cases 
diagnosed within 10 years is highly achievable. We hope to incorporate routine procedures 
for obtaining advance participant consent for access to tumor tissue and pathology reports in 
CHDS routine follow-up.
Recommendations
On the basis of the tissue consent gained from participants in this and other studies,6–9 we 
recommend gaining broad consent from cohort members at enrollment (before cancer 
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diagnosis), which includes permission for subsequent collection of tumor samples. 
Comparing consent rates from several cancer cohort studies, broad consent before diagnosis 
appears to increase the likelihood of obtaining consent to access records and samples 
compared with requesting consent after diagnosis.
We also recommend that future studies collect pathology reports and tumor specimens as 
they become available, because hospitals often destroy samples that are older than 10 years. 
Retention of histopathology slides and paraffin tumor blocks for ten years is consistent with 
guidelines set by the College of American Pathologists (CAP).12 Despite CAP guidelines, 
some hospitals keep samples for longer, although this was the exception rather than the rule. 
Recommendations for other investigators are summarized in Table 3.
Conclusions
This study demonstrates the CHDS’s ability to obtain tissue samples and pathology reports 
in a long-term cohort study from participants who were diagnosed with breast cancer 0–32 
years before collection attempts began. We were most successful in obtaining samples and 
pathology reports from cases diagnosed within the last 10 years. Obtaining consent for 
contact and tissue access at enrollment and maintaining active follow-up to identify new 
cases as they occur is recommended to maximize the acquisition of tumor tissue in long-
term cancer cohorts. Where active follow-up is impractical, linkage to the CCR can identify 
contact information of subjects required to request consent and also institutional sources for 
pathology records and tissue samples. California has one of the most comprehensive tumor 
registries and it is likely that California cohorts can make an important contribution to 
understanding the etiology of cancer.
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Fig. 1. 
Percentage of tumor samples and pathology reports received (received/requested), stratified 
by years since breast cancer diagnosis (year of request – year of diagnosis) for both 
generations combined.
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